Royalty Pharma PLC (RPRX)
28.75
+0.68
(+2.42%)
USD |
NASDAQ |
May 02, 16:00
28.80
+0.05
(+0.17%)
After-Hours: 17:21
Royalty Pharma Revenue (Quarterly): 596.07M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 596.07M |
| September 30, 2023 | 536.31M |
| June 30, 2023 | 538.20M |
| March 31, 2023 | 683.97M |
| December 31, 2022 | 565.75M |
| September 30, 2022 | 573.46M |
| June 30, 2022 | 535.96M |
| March 31, 2022 | 562.05M |
| December 31, 2021 | 575.70M |
| September 30, 2021 | 585.77M |
| Date | Value |
|---|---|
| June 30, 2021 | 554.96M |
| March 31, 2021 | 573.03M |
| December 31, 2020 | 572.14M |
| September 30, 2020 | 538.40M |
| June 30, 2020 | 510.93M |
| March 31, 2020 | 500.88M |
| December 31, 2019 | 457.49M |
| September 30, 2019 | 464.28M |
| June 30, 2019 | 457.61M |
| March 31, 2019 | 434.88M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
457.49M
Minimum
Dec 2019
683.97M
Maximum
Mar 2023
546.47M
Average
554.96M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Viatris Inc | 3.837B |
| Walgreens Boots Alliance Inc | 37.05B |
| Pacira BioSciences Inc | 181.24M |
| Amphastar Pharmaceuticals Inc | 178.10M |
| Maravai LifeSciences Holdings Inc | 74.14M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 494.34M |
| Total Expenses (Quarterly) | -16.83M |
| EPS Diluted (Quarterly) | 1.10 |
| Enterprise Value | 21.00B |
| Profit Margin (Quarterly) | 82.93% |
| Earnings Yield | 8.77% |
| Operating Earnings Yield | 8.61% |
| Normalized Earnings Yield | 6.940 |